OCRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ocera Therapeutics's Enterprise Value is $47.49 Mil. Ocera Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 was $-23.18 Mil. Therefore, Ocera Therapeutics's EV-to-EBIT for today is -2.05.
The historical rank and industry rank for Ocera Therapeutics's EV-to-EBIT or its related term are showing as below:
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ocera Therapeutics's Enterprise Value for the quarter that ended in Sep. 2017 was $23.51 Mil. Ocera Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 was $-23.18 Mil. Ocera Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2017 was -98.59%.
The historical data trend for Ocera Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocera Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | ||||||||||
EV-to-EBIT | Get a 7-Day Free Trial | -1.12 | -10.01 | -3.19 | -1.17 | -1.20 |
Ocera Therapeutics Quarterly Data | ||||||||||||||||||||
Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | |
EV-to-EBIT | Get a 7-Day Free Trial | -1.38 | -1.20 | -0.72 | -0.77 | -1.01 |
For the Biotechnology subindustry, Ocera Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ocera Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ocera Therapeutics's EV-to-EBIT falls into.
Ocera Therapeutics's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 47.490 | / | -23.18 | |
= | -2.05 |
Ocera Therapeutics's current Enterprise Value is $47.49 Mil.
Ocera Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocera Therapeutics (NAS:OCRX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Ocera Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2017 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Sep. 2017 ) | = | EBIT | / | Enterprise Value (Q: Sep. 2017 ) |
= | -23.18 | / | 23.512215 | |
= | -98.59 % |
Ocera Therapeutics's Enterprise Value for the quarter that ended in Sep. 2017 was $23.51 Mil.
Ocera Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Ocera Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian H Dovey | 10 percent owner | ONE PALMER SQUARE, PRINCETON NJ 08542 |
Steven P James | director | C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
Wendall Wierenga | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Nina S Kjellson | director | C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025 |
Domain Partners Viii, L.p. | 10 percent owner | C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542 |
Dp Viii Associates, L.p. | 10 percent owner | C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542 |
Eckard Weber | director | C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542 |
Kim P. Kamdar | 10 percent owner | C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542 |
Brian K Halak | 10 percent owner | C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542 |
Dp Vi Associates, L.p. | 10 percent owner | ONE PALMER SQUARE, PRINCETON NJ 08542 |
Associates Domain | 10 percent owner | ONE PALMER SQUARE, PRINCETON NJ 08542 |
Domain Partners Vi, L.p. | 10 percent owner | ONE PALMER SQUARE, PRINCETON NJ 08542 |
Nicole Vitullo | 10 percent owner | 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
James C Blair | 10 percent owner | 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204 |
Jesse I Treu | 10 percent owner |
From GuruFocus
By Monica Wolfe Monica Wolfe • 07-19-2013
By Monica Wolfe Monica Wolfe • 07-22-2014
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.